269390-69-4

Basic information

• Product Name: N-(4-CHLOROPHENYL)-2-[(PYRIDIN-4-YLMETHYL)AMINO]BENZAMIDE
• Synonyms: N-(4-CHLOROPHENYL)-2-[(PYRIDIN-4-YLMETHYL)AMINO]BENZAMIDE;VEGF RECEPTOR TYROSINE KINASE INHIBITOR II;VEGFR Tyrosine Kinase Inhibitor II
• CAS NO: 269390-69-4
• Molecular Formula: C19H16ClN3O
• Molecular Weight: 337.80284
• Product Categories: Angiogenesis and Metastasis
• Mol File: 269390-69-4.mol

Chemical Properties

• Boiling Point: 463.6±40.0 °C(Predicted)
• Appearance: /
• Density: 1.331±0.06 g/cm3(Predicted)
• PKA: 12.62±0.70(Predicted)
• CAS DataBase Reference: N-(4-CHLOROPHENYL)-2-[(PYRIDIN-4-YLMETHYL)AMINO]BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-CHLOROPHENYL)-2-[(PYRIDIN-4-YLMETHYL)AMINO]BENZAMIDE(269390-69-4)
• EPA Substance Registry System: N-(4-CHLOROPHENYL)-2-[(PYRIDIN-4-YLMETHYL)AMINO]BENZAMIDE(269390-69-4)

Safety Data

• Hazardous Substances Data: 269390-69-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(4-CHLOROPHENYL)-2-[(PYRIDIN-4-YLMETHYL)AMINO]BENZAMIDE is used as a VEGFR Tyrosine Kinase Inhibitor II for its potent inhibitory effects on the kinase activities of KDR, Flt-1, and c-Kit. This application is particularly relevant in the context of cancer therapy, as these kinases are often overexpressed in various types of tumors, contributing to angiogenesis and tumor growth.
Used in Research and Development:
In the field of research and development, N-(4-CHLOROPHENYL)-2-[(PYRIDIN-4-YLMETHYL)AMINO]BENZAMIDE serves as a valuable compound for studying the structure-activity relationships of various molecular targets, including kinases and other enzymes. Its unique chemical structure allows researchers to explore its potential as a lead compound for the development of novel therapeutic agents.
Used in Drug Design and Optimization:
The compound's interaction with molecular targets, such as VEGFR tyrosine kinases, makes it a useful tool in the process of drug design and optimization. By understanding the molecular interactions and binding properties of N-(4-CHLOROPHENYL)-2-[(PYRIDIN-4-YLMETHYL)AMINO]BENZAMIDE, researchers can design and develop more effective and selective inhibitors for various diseases, including cancer.

Upstream product

• 618359-42-5 [2-(4-chlorophenylcarbamoyl)-phenyl]carbamic acid tert-butyl ester 
• 118-92-3 anthranilic acid 
• 68790-38-5 2-(tert-butyloxycarbonylamino)benzoic acid 
• 872-85-5 pyridine-4-carbaldehyde 
• 4943-86-6 2-amino-N-(4-chlorophenyl)benzamide 

Relevant articles and documents

Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr

Inhibition of tumor-induced angiogenesis is a promising strategy in anticancer research. Neovascularization is a process required for both tumor growth and metastasis. Enhanced understanding of the underlying molecular mechanisms has led to the discovery

Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching

The vascular endothelial growth factor (VEGF) tyrosine kinase receptors KDR and Flt-1 are targets of current interest in anticancer drug research. PTK787/ZK222584 is a potent inhibitor of these enzymes in clinical evaluation as an antiangiogenic agent. The development of a hypothesis concerning the bioactive conformation of this compound has led to the discovery of a new class of potent inhibitors of KDR and Flt-1, the anthranilamides. This could be achieved with a limited experimental effort, which only involved the testing of one archive compound and the synthesis and testing of one appropriate analogue.

N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors

Described are compounds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10-(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of